Results 11 to 20 of about 3,746 (131)

4β-Hydroxycholesterol Signals From the Liver to Regulate Peripheral Cholesterol Transporters [PDF]

Frontiers in Pharmacology, 2020
Activation of pregnane X receptor (PXR) elevates circulating 4β-hydroxycholesterol (4βHC), an agonist of liver X receptor (LXR). PXR may also regulate 25-hydroxycholesterol and 27-hydroxycholesterol.
Tuire Salonurmi, Tuire Salonurmi, Heba Nabil, Heba Nabil, Heba Nabil, Justiina Ronkainen, Justiina Ronkainen, Tuulia Hyötyläinen, Heidi Hautajärvi, Markku J. Savolainen, Markku J. Savolainen, Markku J. Savolainen, Ari Tolonen, Matej Orešič, Päivi Känsäkoski, Jaana Rysä, Jukka Hakkola, Jukka Hakkola, Jukka Hakkola, Janne Hukkanen, Janne Hukkanen, Janne Hukkanen   +21 more
doaj   +4 more sources

Role of oxysterol 4β-hydroxycholesterol and liver X receptor alleles in pre-eclampsia [PDF]

Annals of Medicine
Background Liver X receptors (LXRs) are expressed in placenta and may be associated with pre-eclampsia (PE). Oxysterols act as agonists for LXRs. We recently proposed a new blood pressure-regulating circuit with oxysterol 4β-hydroxycholesterol (4βHC ...
Lassi Kaartinen, Tiina Jääskeläinen, Eeva Sliz, Gamze Yazgeldi Gunaydin, Satu Wedenoja, Shintaro Katayama, Eero Kajantie, Valtteri Rinne, Seppo Heinonen, Juha Kere, Heta Merikallio, Eeva Sliz, Hannele Laivuori, Janne Hukkanen   +13 more
doaj   +5 more sources

Liver X Receptor Agonist 4β‐Hydroxycholesterol as a Prognostic Factor in Coronary Artery Disease [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Regardless of progress in treatment of coronary artery disease (CAD), there is still a significant residual risk of death in patients with CAD, highlighting the need for additional risk stratification markers.
Roosa Rahunen, Mikko Tulppo, Valtteri Rinne, Samuli Lepojärvi, Juha S. Perkiömäki, Heikki V. Huikuri, Olavi Ukkola, Juhani Junttila, Janne Hukkanen   +8 more
doaj   +4 more sources

No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. [PDF]

PLoS ONE, 2015
PURPOSE:To investigate the effect of vitamin D3 on hepatic Cytochrome P450 enzyme (CYP) 3A4 in patients with abnormal glucose regulation using the endogenous marker 4β-hydroxycholesterol (4β-OHC):cholesterol ratio.
Buster Mannheimer, Henrik Wagner, Claes-Göran Östenson, Ulf Diczfalusy   +3 more
doaj   +3 more sources

Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation [PDF]

Journal of Lipid Research, 2013
Several previous studies have shown that renal failure decreases not only renal elimination but also metabolic clearance of drugs, particularly those metabolized by CYP3A.
Yosuke Suzuki, Hiroki Itoh, Fuminori Sato, Kanako Kawasaki, Yukie Sato, Takashi Fujioka, Yuhki Sato, Keiko Ohno, Hiromitsu Mimata, Satoshi Kishino   +9 more
doaj   +2 more sources

Serum 4β-hydroxycholesterol increases during fluconazole treatment. [PDF]

Eur J Clin Pharmacol, 2021
Purpose: The antifungal drugs ketoconazole and itraconazole reduce serum concentrations of 4β-hydroxycholesterol, which is a validated marker for hepatic cytochrome P450 (CYP) 3A4 activity.
Lütjohann D, Stellaard F, Kerksiek A, Lötsch J, Oertel BG.   +4 more
europepmc   +3 more sources

Estrogen associations with human pregnancy related increases in cytochrome P450 3A activity [PDF]

Frontiers in Pharmacology
IntroductionIncreased CYP3A-mediated drug clearance during pregnancy can lead to subtherapeutic dosing of CYP3A substrates. Pregnancy-related hormones (PRHs) increase CYP3A4 expression and activity in cultured human hepatocytes.
Muluneh M. Fashe, Jonghwa Lee, Joseph T. Grieco, John K. Fallon, Ian R. Mulrenin, Megan N. Gower, Klarissa D. Jackson, Kim A. Boggess, Craig R. Lee   +8 more
doaj   +2 more sources

CYP3A Activity in End-of-Life Cancer Patients Measured by 4β-Hydroxycholesterol/cholesterol Ratio, in Men and Women. [PDF]

Cancers (Basel), 2021
More than 50% of all drugs are metabolized by the cytochrome P450 3A enzyme (CYP3A). The aim of this study was to investigate if the CYP3A activity, measured by the endogenous marker 4β-hydroxycholesterol/cholesterol ratio (4β-OHC/C), is changed during ...
Bergström H, Helde Frankling M, Klasson C, Lövgren Sandblom A, Diczfalusy U, Björkhem-Bergman L.   +5 more
europepmc   +2 more sources

Comparative performance of oral midazolam clearance and plasma 4β-hydroxycholesterol to explain interindividual variability in tacrolimus clearance. [PDF]

Br J Clin Pharmacol, 2016
We compared the CYP3A4 metrics weight-corrected midazolam apparent oral clearance (MDZ Cl/F/W) and plasma 4β-hydroxycholesterol/cholesterol (4β-OHC/C) as they relate to tacrolimus (TAC) Cl/F/W in renal transplant recipients.status ...
Vanhove T, de Jonge H, de Loor H, Annaert P, Diczfalusy U, Kuypers DR.   +5 more
europepmc   +2 more sources

4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. [PDF]

Br J Clin Pharmacol, 2015
Aim Taxanes are anti-cancer agents used to treat several types of solid tumours. They are metabolized by cytochrome P450 (CYP) 3A, displaying a large pharmacokinetic (PK) variability.
de Graan AJ, Sparreboom A, de Bruijn P, de Jonge E, van der Holt B, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH.   +8 more
europepmc   +2 more sources